Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAS181 for the Treatment of Lower Respiratory Tract Parainfluenza Infection in Immunocompromised Subjects
NCT03808922Phase 3Recruiting
- Sponsor
- Ansun Biopharma
- Start
- May 2019
- Primary completion
- Sep 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 5
01
Overview
A Phase 3 trial of DAS181 in parainfluenza virus infection, coronavirus disease 2019 (COVID-19), sponsored by Ansun Biopharma. Started May 2019; status: recruiting.
02
Drugs
DAS181
03
Conditions
parainfluenza virus infectioncoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT03808922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03808922.